DK2328893T3 - Triazolforbindelser som modulerer hsp90 aktivitet - Google Patents
Triazolforbindelser som modulerer hsp90 aktivitetInfo
- Publication number
- DK2328893T3 DK2328893T3 DK09791292T DK09791292T DK2328893T3 DK 2328893 T3 DK2328893 T3 DK 2328893T3 DK 09791292 T DK09791292 T DK 09791292T DK 09791292 T DK09791292 T DK 09791292T DK 2328893 T3 DK2328893 T3 DK 2328893T3
- Authority
- DK
- Denmark
- Prior art keywords
- hsp90 activity
- compounds modulating
- triazolic compounds
- modulating hsp90
- triazolic
- Prior art date
Links
- 101710113864 Heat shock protein 90 Proteins 0.000 title 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18839708P | 2008-08-08 | 2008-08-08 | |
| PCT/US2009/053157 WO2010017479A1 (en) | 2008-08-08 | 2009-08-07 | Triazole compounds that modulate hsp90 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2328893T3 true DK2328893T3 (da) | 2013-06-17 |
Family
ID=41172462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09791292T DK2328893T3 (da) | 2008-08-08 | 2009-08-07 | Triazolforbindelser som modulerer hsp90 aktivitet |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9126953B2 (da) |
| EP (1) | EP2328893B1 (da) |
| DK (1) | DK2328893T3 (da) |
| ES (1) | ES2415234T3 (da) |
| PL (1) | PL2328893T3 (da) |
| PT (1) | PT2328893E (da) |
| WO (1) | WO2010017479A1 (da) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007021966A1 (en) | 2005-08-12 | 2007-02-22 | Synta Pharmaceuticals Corp. | Pyrazole compounds that modulate hsp90 activity |
| US20070250391A1 (en) * | 2006-04-05 | 2007-10-25 | Prade Hendrik D | Merchandising system and method for food and non-food items for a meal kit |
| WO2007139960A2 (en) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Compounds that modulate hsp90 activity and methods for identifying same |
| DK2035396T3 (da) | 2006-05-25 | 2014-06-02 | Synta Pharmaceuticals Corp | Triazolforbindelser der modulerer hsp90-aktivitet |
| WO2007140002A2 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Method for treating non-hodgkin's lymphoma |
| CA2653222A1 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| US8034834B2 (en) | 2006-05-25 | 2011-10-11 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders with HSP90 inhibitors |
| EP2502628B1 (en) | 2006-06-23 | 2016-12-14 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in cancer |
| CN101679319B (zh) | 2007-02-08 | 2014-07-09 | 辛塔医药品有限公司 | 用于治疗增生性病症如癌症的三唑类化合物 |
| WO2009139916A1 (en) * | 2008-05-16 | 2009-11-19 | Synta Pharmaceuticals Corp. | Tricyclic triazole compounds that modulate hsp90 activity |
| WO2009148599A1 (en) | 2008-06-04 | 2009-12-10 | Synta Pharmaceuticals Corp. | Pyrrole compunds that modulate hsp90 activity |
| US8648071B2 (en) | 2008-06-27 | 2014-02-11 | Synta Pharmaceuticals Corp. | Hydrazonamide compounds that modulate Hsp90 activity |
| TW201011003A (en) | 2008-08-08 | 2010-03-16 | Synta Pharmaceuticals Corp | Triazole compounds that modulate HSP90 activity |
| WO2010060186A1 (en) | 2008-11-03 | 2010-06-03 | Alethia Biotherapeutics Inc. | Antibodies that specifically block the biological activity of a tumor antigen |
| EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
| ES2536980T3 (es) | 2010-12-20 | 2015-06-01 | Sigma-Tau Research Switzerland S.A. | Compuestos aril triazol con actividad antitumoral |
| DK3173427T3 (da) | 2011-03-31 | 2019-08-05 | Adc Therapeutics Sa | Antistoffer mod nyre-associeret antigen 1 og antigen-bindende fragmenter deraf |
| EP2729144A2 (en) | 2011-07-07 | 2014-05-14 | Synta Pharmaceuticals Corp. | Treating cancer with hsp90 inhibitory compounds |
| CN102391260B (zh) * | 2011-09-29 | 2014-12-10 | 上海交通大学 | 3-甲酮-6-取代-苯并呋喃类化合物及其制备方法和用途 |
| CA2853799A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| AU2012332424A1 (en) | 2011-11-02 | 2014-06-05 | Synta Pharmaceuticals Corp. | Combination therapy of Hsp90 inhibitors with platinum-containing agents |
| WO2013074594A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
| HRP20190946T1 (hr) | 2012-01-09 | 2019-07-26 | Adc Therapeutics Sa | Sredstva za liječenje trostruko negativnog raka dojke |
| WO2015066053A2 (en) * | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| CN104447658A (zh) * | 2014-12-04 | 2015-03-25 | 杭州杜易科技有限公司 | 一种卤代4-色满酮衍生物的制备方法 |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| US11724997B2 (en) | 2018-03-01 | 2023-08-15 | Annapurna Bio, Inc. | Compounds and compositions for treating conditions associated with APJ receptor activity |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1817295B1 (en) | 2004-11-18 | 2012-11-07 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| WO2007021966A1 (en) | 2005-08-12 | 2007-02-22 | Synta Pharmaceuticals Corp. | Pyrazole compounds that modulate hsp90 activity |
| WO2007021877A1 (en) | 2005-08-18 | 2007-02-22 | Synta Pharmaceuticals Corp. | Imidazole compounds that modulate hsp90 activity |
| CA2618628C (en) | 2005-08-18 | 2014-11-18 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| WO2007139952A2 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Method for the preparation of triazole compounds with hsp90 modulating activity |
| EP2038262B1 (en) | 2006-05-25 | 2014-11-12 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| DK2035396T3 (da) | 2006-05-25 | 2014-06-02 | Synta Pharmaceuticals Corp | Triazolforbindelser der modulerer hsp90-aktivitet |
| WO2007140002A2 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Method for treating non-hodgkin's lymphoma |
| CA2653222A1 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| US8034834B2 (en) | 2006-05-25 | 2011-10-11 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders with HSP90 inhibitors |
| WO2007139960A2 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Compounds that modulate hsp90 activity and methods for identifying same |
| CA2659425C (en) | 2006-08-17 | 2017-06-20 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| US20110046125A1 (en) | 2006-10-19 | 2011-02-24 | Synta Pharmaceuticals Corp. | Method for treating infections |
| WO2008057246A2 (en) | 2006-10-26 | 2008-05-15 | Synta Pharmaceuticals Corp. | Method for treating inflammatory disorders |
| CN101679319B (zh) * | 2007-02-08 | 2014-07-09 | 辛塔医药品有限公司 | 用于治疗增生性病症如癌症的三唑类化合物 |
| US8993608B2 (en) | 2007-03-12 | 2015-03-31 | Synta Pharmaceuticals Corp. | Method for inhibiting topoisomerase II |
| WO2008118391A2 (en) | 2007-03-27 | 2008-10-02 | Synta Pharmaceuticals Corp. | Triazinone and diazinone derivatives useful as hsp90 inhibitors |
| WO2008153730A2 (en) | 2007-05-25 | 2008-12-18 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with mutations in c-met |
| EP2193135A1 (en) | 2007-08-13 | 2010-06-09 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| WO2009139916A1 (en) | 2008-05-16 | 2009-11-19 | Synta Pharmaceuticals Corp. | Tricyclic triazole compounds that modulate hsp90 activity |
| WO2009148599A1 (en) | 2008-06-04 | 2009-12-10 | Synta Pharmaceuticals Corp. | Pyrrole compunds that modulate hsp90 activity |
| US8648071B2 (en) | 2008-06-27 | 2014-02-11 | Synta Pharmaceuticals Corp. | Hydrazonamide compounds that modulate Hsp90 activity |
| TW201011003A (en) | 2008-08-08 | 2010-03-16 | Synta Pharmaceuticals Corp | Triazole compounds that modulate HSP90 activity |
| RS53716B1 (sr) | 2009-10-19 | 2015-04-30 | Synta Pharmaceuticals Corp. | Kombinovana terapija kancera sa hsp90 inhibitornim jedinjenjima |
| EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
| EP2560641A2 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor |
| US20130172333A1 (en) | 2010-05-20 | 2013-07-04 | Synta Pharmaceuticals Corp. | Formulation and dosing of hsp90 inhibitory compounds |
| EP2575810A1 (en) | 2010-05-24 | 2013-04-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor |
| US20130225870A1 (en) | 2010-08-25 | 2013-08-29 | Synta Pharmaceuticals Corp. | Method of synthesizing substituted 2-alkyl phenols |
| AU2011302344B2 (en) | 2010-09-13 | 2015-01-15 | Synta Pharmaceuticals Corp. | HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients |
| EP2648708A2 (en) | 2010-12-08 | 2013-10-16 | Synta Pharmaceuticals Corp. | Combination for breast cancer therapy with hsp90 inhibitory compounds |
| WO2012096919A1 (en) | 2011-01-11 | 2012-07-19 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors |
| EP2678013A1 (en) | 2011-02-23 | 2014-01-01 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with radiotherapy |
| CN103391779A (zh) | 2011-02-24 | 2013-11-13 | 辛塔医药品有限公司 | 使用hsp90抑制性化合物的前列腺癌治疗 |
| US20140045908A1 (en) | 2011-02-25 | 2014-02-13 | Synta Pharmaceuticals Corp. | Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers |
| US8628752B2 (en) | 2011-10-28 | 2014-01-14 | Synta Pharmaceuticals Corp. | Methods of identifying HSP90 inhibitors with less ocular toxicity |
-
2009
- 2009-08-07 ES ES09791292T patent/ES2415234T3/es active Active
- 2009-08-07 DK DK09791292T patent/DK2328893T3/da active
- 2009-08-07 WO PCT/US2009/053157 patent/WO2010017479A1/en not_active Ceased
- 2009-08-07 EP EP20090791292 patent/EP2328893B1/en active Active
- 2009-08-07 US US13/057,962 patent/US9126953B2/en active Active
- 2009-08-07 PT PT97912927T patent/PT2328893E/pt unknown
- 2009-08-07 PL PL09791292T patent/PL2328893T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2328893T3 (pl) | 2013-09-30 |
| EP2328893B1 (en) | 2013-03-20 |
| ES2415234T3 (es) | 2013-07-24 |
| WO2010017479A1 (en) | 2010-02-11 |
| US20110224206A1 (en) | 2011-09-15 |
| EP2328893A1 (en) | 2011-06-08 |
| US9126953B2 (en) | 2015-09-08 |
| PT2328893E (pt) | 2013-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2328893T3 (da) | Triazolforbindelser som modulerer hsp90 aktivitet | |
| DK2035396T3 (da) | Triazolforbindelser der modulerer hsp90-aktivitet | |
| DK2364293T3 (da) | Hidtil ukendte pyrazol-4-N-alkoxycarboxamider som mikrobiocider | |
| HUS1900016I1 (hu) | C7-fluorral helyettesített tetraciklin vegyületek | |
| DK2369934T3 (da) | Spiroheterocykliske n-oxypiperidiner som pesticider | |
| BRPI0917369A2 (pt) | Compostos inseticidas | |
| BRPI0918500A2 (pt) | compostos inseticidas | |
| BRPI0917188A2 (pt) | Compostos inseticidas | |
| NO2021006I1 (no) | Quofenix, delafloksacin | |
| DK2288375T3 (da) | Pegylerede insulin-lispro-forbindelser | |
| BRPI0920707A2 (pt) | compostos | |
| DK2242759T3 (da) | Forbindelser | |
| BRPI0819093A2 (pt) | compostos moduladores de sirtuína | |
| DK2291368T3 (da) | Substitueret gamma-lactam som terapeutisk middel | |
| BRPI1007310A2 (pt) | Compostos inseticidas. | |
| DK2144897T3 (da) | 8-Oxy-quinolinderivater som bradykinin B2-receptormodulatorer | |
| BRPI0909656A2 (pt) | Microencapsulamento | |
| ITBO20080040A1 (it) | Tagliaerba. | |
| DK2612845T3 (da) | Aromatisk forbindelse som indeholder specifik forgrening | |
| BRPI0922464A2 (pt) | Combinações de compostos ativos | |
| DK2401256T3 (da) | Forbindelser som bradykinin-B1-antagonister. | |
| DK2297162T3 (da) | Forbindelser | |
| DK2373652T3 (da) | Substituerede piperidin-spiro-pyrrolidinon- og piperidinon-forbindelser anvendt som h3-modulatorer | |
| BRPI0916432A2 (pt) | compostos | |
| BRPI0912716A2 (pt) | composto. |